Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK102 injection in high-risk hypercholesterolemia (phase II)
CTR20200119Phase 2Completed
- Sponsor
- Kangrong Oriental
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ebronucimab in hypercholesterolemia, dyslipidemia, sponsored by Kangrong Oriental. Started Feb 2020; status: completed.
02
Drugs
ebronucimab
03
Conditions
hypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on CTR20200119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200119.